Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085631 (agitation)
 12,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Bromperidol has a safe antipsychotic effect. The latency is short, the effect is definite on the seventh treatment day and is already seen in particular symptoms on the third treatment day. Beside the antipsychotic effect, the substance has slight sedative properties, an anxiolytic effect and an evident influence on the complex phenomenon of social re-integration. The sedative effect is not sufficient in severe psychomotor agitation; here it is necessary to combine it with a sedative neuroleptic or other sedating substance. The clinical effect is safe for 24 hours. Due to the small doses (3-12 mg daily), bromperidol belongs to the neuroleptics of high potency. The high potency, the 24 hour efficiency and the low sedation qualify the substance for the long-term treatment of schizophrenic psychoses. Extrapyramidal effects occur in relation to the high potency and are easily corrected by an anticholinergic drug.
 ...
PMID:Treatment of female schizophrenic patients with bromperidol, a new neuroleptic drug of the butyrophenone group with medium duration of action. 34 74

The author has given bromperidol to a first group of fifteen patients with a clear psychotic condition, mostly of the schizophrenic type. The results of this study show that this neuroleptic drug possesses potent antipsychotic properties, being thus very interesting in the treatment of productive psychosis. Its antimanic activity is, however, not pronounced. Therefore, it is not indicated in agitation states requiring heavy and immediate sedation. The general tolerability of the product is excellent. Its side-effects are mostly of the extrapyramidal type, generally mild and easily controlled by antiparkinson medications. Bromperidol, given in one single daily dose, is well accepted by the patients. It is therefore a valuable addition in the neuroleptic therapy as concerns prevention of relapses in psychotic conditions. Its stimulating properties on activity, concentration and socioprofessional adaptation make it particularly adequate for readaptation programs.
 ...
PMID:Clinical trial with bromperidol in psychotic states. 64 4